leisure time -WSS

leisure time

author：explore 2025-09-27 22:48:10 - browse：24772

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

entertainment

focus

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

AbbVie dramatically boosts its spending on lobbying

Providers still hesitate to prescribe buprenorphine, study finds

HHS secretary Becerra pressed on Change HealthCare cyberattack

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Wikipedia

leisure time

focus

At least 13 dead in Texas as scorching temps continue

Review: 'Barbie' will hit you like a shot in the heart

Medicare proposal to cover medical devices draws a mixed reaction

As Taiwan prepares for anti

In age of alternative facts, a scholarly course on calling out crap

As Taiwan prepares for anti

Wildfire smoke exposes gaps in outdoor worker protections

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

Readout Newsletter: CAR

How many hemophilia patients actually want gene therapy?

Elizabeth Warren probes abortion access

UCLA team creates talking throat patch for voice disorders

Medicare coverage of Wegovy, once blocked, now looks possible

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

focus

entertainment

focus

entertainment